CenterPoint Energy
CNP
$41.07
-0.32%
CenterPoint Energy, Inc. is a regulated utility holding company whose electric transmission and distribution utilities serve more than 2.5 million customers across the Houston metropolitan area, southern Indiana, and west central Ohio, complemented by natural gas distribution operations and other portfolio businesses. As one of the largest electric utilities in Texas, CenterPoint occupies a structurally entrenched position as a monopoly service provider in its footprint, with earnings anchored by regulated rate-base growth rather than commodity or competitive dynamics. The current investor narrative centers on the company's outsized capital investment program to harden and expand Houston-area grid infrastructure amid rapid data-center and industrial load growth, balanced against persistent concerns about the funding of that capex, elevated leverage, and a deeply negative free cash flow profile. Recent quarterly results showing double-digit revenue growth and margin expansion have revived interest, but the stock's underperformance relative to the broader market over the past year keeps the debate focused on execution, regulatory outcomes, and balance-sheet capacity.…
CNP
CenterPoint Energy
$41.07
Investment Opinion: Should I buy CNP Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness. The core thesis is that CenterPoint offers regulated growth exposure to Houston's data-center-driven load expansion, but the premium valuation (23.81x trailing PE, 13.22x EV/EBITDA) and balance-sheet strain (2.12x debt-to-equity, -$2.695 billion FCF) limit near-term upside. The analyst consensus is 'buy' with a mean rating of 2.16 and an average target of $44.12, implying 8.8% upside, but the risk/reward is balanced given the 6.3% downside to the low target of $38.00.
The supporting evidence includes 10.7% revenue growth in Q2 2026, 22.6% EBITDA growth to $1.003 billion, and operating margin expansion to 24.81% from 21.45%. However, these positives are offset by a PEG ratio of 12.54x, indicating the growth is expensive relative to the multiple, and a dividend yield of 2.29% that is below the sector average and not covered by free cash flow. The forward PE of 19.41x suggests the market expects earnings growth, but the 18.5% compression from trailing to forward multiple may be optimistic given the capex funding needs.
The biggest risks that could invalidate the thesis are a adverse regulatory outcome in Texas that delays capex recovery, a further increase in interest expense (already up to $261 million in Q2 2026 from $195 million), and a dividend cut or equity raise that dilutes shareholders. The rating would upgrade to Buy if the stock pulls back toward the $38 analyst low target (offering 16% upside to the average target) or if free cash flow turns positive. It would downgrade to Sell if the dividend is cut or if regulatory outcomes materially impair the rate-base growth story. Relative to history and peers, the stock appears overvalued on most metrics, but the growth premium may be justified if execution continues.
Sign up to view all
CNP 12-Month Price Forecast
The forward-looking view is balanced: CenterPoint offers above-average growth for a utility, but the premium valuation and balance-sheet leverage limit upside. The base case (55% probability) targets $42-$46, aligned with the analyst average, while the bear case (20%) targets $36-$38 on regulatory or financial setbacks. The bull case (25%) targets $45-$49 if data-center demand accelerates and regulatory outcomes are favorable. I would upgrade to bullish if free cash flow turns positive or if the stock pulls back toward $38, and downgrade to bearish if the dividend is cut or leverage increases further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CenterPoint Energy's 12-month outlook, with a consensus price target around $44.00 and implied upside of +7.1% versus the current price.
Average Target
$44.00
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $49
Analyst target range
Seventeen analysts cover CenterPoint with a consensus recommendation of "buy" (mean rating of 2.16 on a scale where lower is more bullish), and the average target price of $44.12 implies roughly 8.8% upside from the current $40.55. The distribution of recent institutional ratings leans constructive but not euphoric: Truist Securities (Buy), KeyBanc (Overweight), and BMO Capital (Outperform) are positive, while Morgan Stanley (Equal Weight), Evercore ISI (In Line), and JP Morgan (Neutral) remain on the sidelines, and notably no firm has issued a downgrade in the recent ratings history. The consensus is therefore moderately bullish, with the buy-rated analysts focused on load growth and capex-driven earnings, while the neutral camp emphasizes valuation and balance-sheet leverage.
The target range of $38.00 to $49.00 is moderately wide — a 29% spread from low to high — signaling meaningful dispersion in assumptions. The $49.00 high target likely assumes accelerating rate-base growth from Houston data-center demand, successful regulatory recovery of capex, and multiple expansion toward the upper end of the historical PE band; the $38.00 low target, which sits just 6.3% below the current price, prices in margin compression from rising interest expense, funding pressure from negative free cash flow, and a de-rating toward the lower end of the historical valuation range. The fact that the low target is only modestly below the current price suggests limited downside conviction even among bears, while the unchanged ratings across firms indicate stable sentiment rather than a catalyst-driven upgrade cycle; the wide spread warrants position-sizing discipline given the stock's low beta but high fundamental leverage.
Drowning in data?
Find the real signal!
Bulls vs Bears: CNP Investment Factors
The bear case currently has stronger evidence due to the combination of elevated leverage (2.12x debt-to-equity), deeply negative free cash flow (-$2.695 billion), and a premium valuation (23.81x PE, 13.22x EV/EBITDA) that leaves little room for disappointment. However, the bull case is supported by tangible operational improvements: 10.7% revenue growth, 22.6% EBITDA growth, and margin expansion, plus a consensus buy rating with 8.8% upside to the average target. The single most important tension is whether the capex-driven rate-base growth can translate into sufficient earnings to justify the premium multiple and fund the dividend without further equity dilution. Resolution of this tension hinges on regulatory outcomes in Texas and the company's ability to manage its balance sheet amid rising interest expenses.
Bullish
- Regulated monopoly with structural growth: CenterPoint's electric T&D utilities serve over 2.5 million customers in Houston, southern Indiana, and Ohio, providing a regulated monopoly with predictable rate-base growth. Q2 2026 revenue rose 10.7% YoY to $2.152 billion, driven by Houston-area load expansion, and EBITDA grew 22.6% to $1.003 billion, demonstrating operating leverage.
- Margin expansion and earnings growth: Operating margin expanded to 24.81% in Q2 2026 from 21.45% a year earlier, while net margin improved to 11.34% from 10.19%. Net income rose to $244 million from $198 million, and forward EPS consensus of $2.68 implies meaningful growth from trailing levels, supporting the 18.5% trailing-to-forward PE compression.
- Analyst consensus buy with upside: Seventeen analysts rate the stock a 'buy' with a mean rating of 2.16 and an average target price of $44.12, implying 8.8% upside from $40.55. The high target of $49.00 suggests 20.8% upside, and no recent downgrades indicate stable sentiment.
- Low beta and defensive characteristics: With a beta of 0.459, CenterPoint is roughly 54% less volatile than the market, offering defensive positioning during market turbulence. The 2.29% dividend yield, though below sector average, provides income with a 54.6% payout ratio covered by earnings.
Bearish
- Elevated leverage and weak interest coverage: Debt-to-equity stands at 2.12x with total debt to capitalization at 68.2%, and interest coverage is a thin 2.05x. Interest expense rose to $261 million in Q2 2026 from $195 million a year earlier, consuming a growing share of operating income and leaving limited cushion if rates rise or regulatory outcomes disappoint.
- Deeply negative free cash flow: Trailing-twelve-month free cash flow is -$2.695 billion, driven by $1.37 billion of Q2 2026 capex against $778 million of operating cash flow. The company relies on external financing, including a $165 million common stock issuance in Q2, making the dividend dependent on continued capital-market access.
- Premium valuation versus utility peers: The trailing PE of 23.81x and EV/EBITDA of 13.22x are well above the typical regulated utility range of high-teens PE and 9-11x EV/EBITDA. Price-to-book at 2.24x is near the top of its multi-year range of 1.68x-2.47x, and the PEG ratio of 12.54x signals the growth embedded in the multiple is expensive.
- Relative underperformance and technical weakness: The stock has gained only 2.22% over the past year versus SPY's 15.53%, a 13.31 percentage point underperformance. It remains down 5.98% over three months and 5.70% over six months, and the 18.69% max drawdown reflects meaningful selling pressure despite the recent bounce.
CNP Technical Analysis
CenterPoint is in a range-bound consolidation phase with a modestly positive longer-term tilt, having gained 2.22% over the trailing year while the S&P 500 advanced 15.53%, a relative underperformance of 13.31 percentage points. At the current price of $40.55, the stock sits at roughly 47% of its 52-week range of $36.37 to $45.26, placing it in the lower-middle of the band rather than at either extreme, which suggests neither momentum-driven overextension nor a distressed falling-knife setup. The 18.69% maximum drawdown over the period confirms the stock has absorbed meaningful selling pressure without breaking down to new lows.
Short-term momentum has turned decisively positive and is diverging from the medium-term trend: the stock is up 5.79% over the past month versus a 1.22% gain for SPY, producing a relative strength of +4.57, yet it remains down 5.98% over three months and 5.70% over six months. This pattern of a sharp one-month rebound inside a three-to-six-month decline is characteristic of mean reversion off a washed-out base rather than a confirmed trend reversal, and the recent sequence of higher closes from $36.62 on September 28 to $40.55 on October 16 supports a constructive near-term setup. The most recent session added 1.88% on volume of roughly 6.23 million shares, indicating genuine buying interest behind the bounce, though the 7.41 short ratio suggests short sellers are not yet capitulating.
Key technical levels are well defined: support rests at the 52-week low of $36.37, which was tested in late September and held, while resistance sits at the 52-week high of $45.26, last approached in late June. A breakout above $45.26 would signal a fresh leg higher and likely validate the load-growth and capex story, whereas a breakdown below $36.37 would mark a lower low and put the dividend-support narrative under pressure. With a beta of just 0.459, CenterPoint is roughly 54% less volatile than the market, meaning its moves are muted relative to SPY and position sizing can be larger for equivalent risk budget, but it also implies the stock will likely lag in strong risk-on rallies.
Beta
0.46
0.46x market volatility
Max Drawdown
-18.7%
Largest decline past year
52-Week Range
$36-$45
Price range past year
Annual Return
+3.7%
Cumulative gain past year
| Period | CNP Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | -1.0% |
| 3m | -7.8% | +2.9% |
| 6m | -3.3% | +6.5% |
| 1y | +3.7% | +13.1% |
| ytd | +6.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNP Fundamental Analysis
Revenue is growing at a healthy clip, with Q2 2026 revenue of $2.152 billion representing 10.7% year-over-year growth versus $1.944 billion in Q2 2025, and the multi-quarter trend is constructive: Q1 2026 revenue of $2.975 billion edged past Q1 2025's $2.920 billion, while Q4 2025's $2.505 billion exceeded Q4 2024's $2.262 billion. Segment data shows Electric Transmission & Distribution contributing $1.381 billion and the Natural Gas segment $777 million, confirming that the regulated electric utility is the dominant growth engine, consistent with Houston-area load expansion. The trajectory implies a utility entering a higher-growth capex cycle, though the sequential volatility between quarters (Q1 revenue is seasonally much larger than Q2) means investors should focus on the year-over-year comparison rather than quarter-to-quarter changes.
Profitability is solid and improving: Q2 2026 net income reached $244 million on a 11.34% net margin, up from $198 million and a 10.19% net margin in Q2 2025, while operating income rose to $534 million from $417 million and operating margin expanded to 24.81% from 21.45%. Gross margin in Q2 2026 was 86.94%, though this figure is inflated by the utility's cost-of-revenue accounting treatment and is not comparable to the 28.71% gross margin reported in the key metrics snapshot; the more meaningful signal is the operating margin of 22.55% and net margin of 11.24%, which are consistent with regulated electric utility norms. EBITDA grew to $1.003 billion in Q2 2026 from $818 million a year earlier, a 22.6% increase that underscores operating leverage as the rate base expands.
Balance-sheet leverage is the principal fundamental risk: debt-to-equity stands at 2.12x, total debt to capitalization is 68.2%, and interest coverage is a thin 2.05x, leaving limited cushion if rates rise or regulatory outcomes disappoint. Free cash flow is deeply negative at -$2.695 billion on a trailing-twelve-month basis, driven by heavy capital expenditure of $1.37 billion in Q2 2026 alone against operating cash flow of $778 million, meaning the company depends on external financing to fund growth — a $165 million common stock issuance in Q2 and active debt management confirm this reliance. ROE of 9.43% and ROA of 3.00% are modest but typical for a regulated utility, while the current ratio of 0.91 signals tight near-term liquidity; the 2.29% dividend yield with a 54.6% payout ratio appears covered by earnings but is not covered by free cash flow, making the dividend dependent on continued capital-market access.
Quarterly Revenue
$2.2B
2026-06
Revenue YoY Growth
+10.7%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$-2.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNP Overvalued?
Because CenterPoint is profitable — Q2 2026 net income of $244 million and trailing EPS of $0.042 (distorted by quarterly timing) — the PE ratio is the appropriate primary metric, and the trailing PE of 23.81x versus a forward PE of 19.41x implies the market expects meaningful earnings growth, consistent with consensus EPS of $2.68 for the forward period. The 18.5% compression from trailing to forward multiple signals that analysts anticipate the capex program translating into rate-base earnings, though the PEG ratio of 12.54x warns that the growth embedded in the multiple is expensive relative to the earnings trajectory.
Against utility-sector norms, CenterPoint's 23.81x trailing PE and 2.24x price-to-book sit at a premium to the typical regulated electric peer, which generally trades in the high-teens PE range and roughly 1.5-2.0x book; the 2.68x price-to-sales and 13.22x EV/EBITDA are likewise rich for a utility, with the EV/EBITDA multiple well above the 9-11x range common among large-cap regulated peers. The premium is partially justified by above-average revenue growth of 10.7% and Houston's data-center-driven load growth, but the 2.12x debt-to-equity and negative free cash flow argue that the market is paying up for a growth story that carries above-average financial risk. The 2.29% dividend yield is below the sector average, reinforcing that investors are buying growth rather than income.
Historically, CenterPoint's PE has ranged from roughly 12.9x (Q1 2024) to 42.9x (Q2 2023), with the current 23.81x sitting near the middle of that band but above the 20-21x levels seen through much of 2024 and 2025. Price-to-book at 2.24x is near the top of its multi-year range of roughly 1.68x to 2.47x, and price-to-sales at 2.68x compares favorably to the 6.9x-13.4x historical prints only because those figures reflect a different share-count and revenue base. The read-through is that the market is pricing in optimistic expectations for rate-base growth and margin expansion, leaving limited room for disappointment on regulatory outcomes or capex funding.
PE
23.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.2x
Enterprise Value Multiple
Investment Risk Disclosure
CenterPoint's financial and operational risks are dominated by its balance-sheet leverage and cash burn. Debt-to-equity of 2.12x and total debt to capitalization of 68.2% are elevated for a regulated utility, and interest coverage of only 2.05x means a modest decline in operating income could pressure the dividend. Free cash flow is deeply negative at -$2.695 billion TTM, with Q2 2026 capex of $1.37 billion far exceeding operating cash flow of $778 million, forcing reliance on external financing including a $165 million equity issuance. The current ratio of 0.91 signals tight near-term liquidity, and the 54.6% payout ratio, while covered by earnings, is not covered by free cash flow, making the dividend dependent on continued capital-market access.
Market and competitive risks center on valuation compression and regulatory exposure. At 23.81x trailing PE and 13.22x EV/EBITDA, CenterPoint trades at a premium to the typical regulated utility (high-teens PE, 9-11x EV/EBITDA), leaving room for multiple contraction if growth disappoints or interest rates remain elevated. The beta of 0.459 indicates low market correlation, but the stock has underperformed SPY by 13.31 percentage points over the past year, and sector rotation away from utilities could exacerbate relative weakness. Regulatory risk is significant given the company's reliance on rate cases in Texas and Indiana to recover capex; adverse outcomes could delay or reduce returns on the $1.37 billion quarterly investment program. No recent news highlights emerging threats, but the wide analyst target range of $38-$49 (29% spread) reflects meaningful dispersion in assumptions about regulatory and financial outcomes.
In a worst-case scenario, a combination of a adverse regulatory ruling in Texas, rising interest rates increasing borrowing costs, and a market de-rating of utility multiples could drive the stock toward its 52-week low of $36.37 or the analyst low target of $38.00. From the current price of $40.55, that represents a downside of approximately -10.3% to the 52-week low and -6.3% to the analyst low target. A more severe scenario, such as a dividend cut or equity raise at a discount, could push the stock below the 52-week low, with the 18.69% max drawdown suggesting a potential decline to around $33, or -18.6% from current levels. The low beta may cushion the downside relative to the market, but the fundamental leverage amplifies company-specific risks.
FAQ
The key risks are financial, regulatory, and market-related. Financial risks include elevated leverage (2.12x debt-to-equity) and negative free cash flow (-$2.695 billion), which could lead to a dividend cut or equity dilution. Regulatory risks involve adverse rate case outcomes in Texas and Indiana that could delay or reduce returns on the $1.37 billion quarterly capex program. Market risks include valuation compression if interest rates remain high or if the stock's premium multiple contracts toward peer levels. Company-specific risks include slower-than-expected data-center load growth and rising interest expense (up to $261 million in Q2 2026 from $195 million). Ranked by severity: financial leverage and cash burn are most critical, followed by regulatory outcomes, then valuation compression.
The 12-month forecast has three scenarios: bull case (25% probability) targets $45-$49, assuming accelerating data-center demand and favorable regulatory outcomes; base case (55%) targets $42-$46, aligned with the analyst average of $44.12 and steady execution; bear case (20%) targets $36-$38, assuming regulatory setbacks or financial stress. The base case is most likely, with the key assumption being revenue growth of 8-10% and stable margins. The analyst consensus target of $44.12 implies 8.8% upside, but the wide range of $38-$49 reflects uncertainty. The stock's low beta (0.459) suggests muted moves relative to the market.
CNP appears overvalued relative to its peers and its own history. The trailing PE of 23.81x and EV/EBITDA of 13.22x are well above the typical regulated utility range of high-teens PE and 9-11x EV/EBITDA. Price-to-book at 2.24x is near the top of its multi-year range of 1.68x-2.47x, and the PEG ratio of 12.54x indicates the growth is expensive. The market is paying a premium for Houston's data-center-driven load growth and margin expansion, but this leaves little room for disappointment. The forward PE of 19.41x suggests the market expects earnings growth, but the 18.5% compression from trailing to forward multiple may be optimistic given the capex funding needs. Overall, the stock is overvalued on most metrics, but the premium may be justified if execution continues.
From a risk/reward perspective, CNP is a moderate buy for long-term investors, but the current price of $40.55 offers limited upside to the analyst average target of $44.12 (8.8%). The stock trades at a premium valuation (23.81x trailing PE) with elevated leverage (2.12x debt-to-equity) and negative free cash flow (-$2.695 billion), which are significant risks. However, the regulated monopoly in Houston provides stable cash flows and growth from data-center demand, and the 2.29% dividend yield adds income. The biggest downside risk is a regulatory setback or dividend cut, which could push the stock toward the 52-week low of $36.37 (-10.3%). For investors with a long-term horizon and tolerance for utility-sector volatility, accumulating on dips toward $38 could be attractive.
CNP is more suitable for long-term investment (minimum 2-3 years) given its regulated utility model, capex-heavy growth cycle, and dividend. The low beta of 0.459 and stable cash flows make it a defensive holding, but the negative free cash flow and leverage require time for the capex program to translate into earnings. Short-term trading is less attractive due to the stock's range-bound behavior (52-week range $36.37-$45.26) and low volatility. The dividend yield of 2.29% provides some income, but the payout ratio of 54.6% and negative FCF mean dividend growth may be limited. A suggested minimum holding period of 2-3 years allows time for rate-base growth to materialize and for the balance sheet to deleverage.